Epitalon

What it is

Epitalon, also spelled Epithalon or Epithalone, is a synthetic four-amino-acid peptide with the sequence AEDG^{[1 ]}. It is commonly described as a synthetic analog related to epithalamin, a pineal gland peptide preparation studied by Vladimir Khavinson and collaborators in gerontology and neuroendocrine research^{[9 –13 ]}. The names are often conflated online, but epithalamin and epitalon are not identical products.

Chemical structure

Epitalon is a synthetic tetrapeptide with sequence Ala-Glu-Asp-Gly, also written AEDG, and molecular formula C14H22N4O9^{[1 ]}. It was developed as a short peptide related to epithalamin, a pineal gland peptide preparation, and has been studied mainly in Russian and Eastern European bioregulator research programs, animal models, and cell-culture telomere studies^{[9 –17 ]}.

Mechanism and rationale

The scientific rationale for epitalon centers on pineal function, melatonin rhythm, cellular aging, and telomere biology^{[9 –17 ]}. Older human studies often evaluated epithalamin, not purified synthetic epitalon, in elderly or cardiovascular populations^{[9 –12 ]}. Animal and primate studies examined epitalon effects on melatonin, cortisol, and neuroendocrine regulation^{[13 –14 ]}. More recent cell-line research has examined whether epitalon affects telomerase activity and telomere length^{[17 ]}.

Epitalon is frequently marketed in longevity and anti-aging communities as a “telomere peptide” or sleep/circadian peptide. These consumer claims are broader than the evidence supports. Cell-culture changes in telomerase or telomere length do not establish human anti-aging efficacy, and older epithalamin studies do not establish that injectable epitalon extends lifespan or treats insomnia in modern clinical practice^{[9 –17 ]}.

FDA’s July 2026 PCAC agenda identifies insomnia as the evaluated use for epitalon-related bulk drug substances^{[4 ]}. That agenda item means FDA plans to consult its advisory committee about possible 503A bulks-list inclusion; it does not mean epitalon has been shown to treat insomnia or that FDA has approved it^{[2 –5 ]}.

When sold online, epitalon is usually presented as a research peptide, anti-aging peptide, sleep peptide, or telomere-support peptide. No FDA-approved epitalon product exists, and there is no approved route, dose, indication, contraindication profile, drug-interaction framework, or long-term safety label^{[2 –7 ]}.

Regulatory status

Epitalon is not FDA-approved for any indication in the United States. No FDA-approved prescription product containing epitalon was identified in FDA materials reviewed for this draft^{[2 –7 ]}.

April 2026 503A removal — procedural, not authorization

Under section 503A, state-licensed pharmacies and physicians may compound using a bulk drug substance only if the substance complies with an applicable USP/NF monograph, is a component of an FDA-approved drug product if no monograph exists, or appears on FDA’s 503A bulks list^{[2 ]}. FDA’s April 22, 2026 503A update states that “Epitalon” was removed from Category 2 because nominations were withdrawn and that FDA intends to consult the Pharmacy Compounding Advisory Committee on July 24, 2026 regarding possible inclusion of epitalon acetate and epitalon free base on the 503A bulks list^{[3 ]}.

Removal from Category 2 is not FDA approval and does not itself authorize compounding. Epitalon is not listed in 503A Category 1 in the April 22, 2026 document and was not identified on the 503A bulks list reviewed for this draft^{[2 –3 ]}. FDA’s July 2026 PCAC agenda lists insomnia as the evaluated use^{[4 ]}.

503B and FDA safety-risk listing

Under section 503B, outsourcing facilities may compound from bulk drug substances only if the substance appears on FDA’s 503B bulks list or the compounded drug appears on FDA’s shortage list at the time of compounding, distribution, and dispensing^{[6 ]}. Epitalon was not identified on the FDA 503B bulks list reviewed for this draft^{[7 ]}.

FDA’s safety-risk page lists Epitalon among withdrawn nominated substances and states that compounded drugs containing epitalon may pose immunogenicity risk for certain routes of administration due to potential aggregation and peptide-related impurities^{[5 ]}. FDA also states that it has not identified safety-related information for the proposed route of administration and therefore lacks sufficient information to know whether epitalon would harm humans^{[5 ]}.

Controlled-substance and anti-doping status

Epitalon was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed for this draft^{[8 ]}. Anti-doping status is less explicit than for MOTS-c or BPC-157. WADA’s S0 category covers non-approved pharmacological substances with no current approval for human therapeutic use, but epitalon was not identified as a named substance in the WADA materials reviewed for this draft; athletes should verify status with their sport’s anti-doping authority before relying on absence of a name from a list.

Date of last regulatory verification: May 5, 2026.

Research summary

Epitalon has a mixed evidence base: older human studies of epithalamin, animal and primate studies of epitalon or related pineal peptide preparations, and modern cell-culture work on telomere biology. These bodies of evidence should not be merged into a single claim that epitalon is clinically proven for anti-aging or insomnia.

Older epithalamin clinical studies

The most cited human longevity-related publication is a 15-year follow-up report by Korkushko and colleagues involving elderly coronary patients with accelerated cardiovascular aging^{[9 ]}. In the underlying randomized comparative study, 39 coronary patients reportedly received epithalamin courses in addition to basic therapy, while 40 controls received basic therapy alone^{[9 ]}. The authors reported differences in cardiovascular aging measures, melatonin rhythm, carbohydrate and lipid metabolism, physical endurance, and mortality^{[9 ]}. However, this was epithalamin, not purified synthetic epitalon; the study is small, older, and not equivalent to a modern FDA registration trial.

Other human epithalamin studies evaluated melatonin rhythm, blood pressure patterns, and immune-endocrine rhythms in elderly or cardiovascular populations^{[10 –12 ]}. These studies support historical interest in pineal peptide preparations but have limited generalizability because they were small, often published in translated or regional journals, and did not use modern FDA-style clinical development standards.

Animal and primate studies

Animal and primate studies more directly involve epitalon. Goncharova and colleagues evaluated epitalon effects on melatonin and cortisol secretion in female rhesus monkeys of different ages^{[13 ]}. Khavinson and colleagues reported neuroendocrine effects in senescent monkeys^{[14 ]}. Kost and colleagues studied epitalon effects on enkephalin-degrading enzymes in human serum and opioid receptor binding in rat brain membrane fractions^{[15 ]}. These studies are mechanistic and exploratory; they do not establish human clinical efficacy.

Telomere — cell-culture only

The telomere claim is based mainly on cell-culture research. Khavinson and colleagues reported in 2003 that epithalon induced telomerase activity and telomere elongation in human somatic cells^{[16 ]}. Al-dulaimi and colleagues later reported in Biogerontology that epitalon increased telomere length in human cell lines through telomerase upregulation or alternative lengthening of telomeres activity, with a published correction to figures in 2025^{[17 –18 ]}. These findings are relevant to mechanism and safety review; they do not show that epitalon slows aging, extends lifespan, improves sleep, or reduces disease risk in humans.

Where the evidence ends

No completed, peer-reviewed, randomized human clinical trial of synthetic epitalon for insomnia was identified for this draft. FDA’s July 2026 PCAC review may evaluate the evidence for insomnia in the context of compounding policy, but no conclusion should be drawn before the meeting materials and any FDA decision are reviewed^{[4 ]}.

Overall, the evidence quality is limited and highly concentrated. Epitalon should be described as an investigational tetrapeptide with mechanistic cell-line and animal data, older epithalamin clinical literature, and no FDA approval. Anti-aging, longevity, telomere-extension, and sleep claims should be presented as claims under investigation rather than established clinical effects.

Public discourse

Terry Roberts, PhD, molecular biologist at Brunel University London, discussed how his laboratory work on epitalon was being cited online as proof of human longevity effects even though the study was conducted in cells^{[19 ]}.

Rachael Dickman, PhD, UCL School of Pharmacy researcher, discussed the difficulty of translating peptide findings from preclinical research into human therapies^{[20 ]}.

Robert F. Kennedy Jr., US Secretary of Health and Human Services, discussed peptides broadly in the context of FDA compounding restrictions; his comments were not a clinical endorsement of epitalon specifically^{[21 ]}.

Eric Topol, MD, Scripps Research Translational Institute, criticized the possible loosening of access to unapproved peptides without stronger clinical evidence^{[22 ]}.

Beth Mole, PhD, senior health reporter at Ars Technica, named Epitalon among the seven peptides scheduled for PCAC review and emphasized that FDA’s listed uses do not equal proven uses^{[23 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Epitalon has no FDA-approved prescribing information. There is therefore no FDA-reviewed label establishing contraindications, common adverse reactions, drug interactions, pregnancy or lactation safety, carcinogenicity data, or long-term monitoring recommendations^{[2 –7 ]}.

Compounding-related risks

FDA’s compounding safety concerns include immunogenicity risk for certain routes of administration and complexities related to peptide aggregation, peptide-related impurities, and API characterization^{[5 ]}. FDA also states that it has not identified adequate safety-related information for the proposed route of administration^{[5 ]}.

Telomere biology and cancer-relevant concerns

Theoretical safety concerns are closely tied to the telomere literature. Telomerase activation and telomere-length maintenance are biologically relevant to aging research, but they are also relevant to cancer biology. The 2025 cell-line study reported telomere length changes in normal cells and cancer cell lines, including findings involving alternative lengthening of telomeres activity in cancer cells^{[17 –18 ]}. This does not prove epitalon causes cancer, but it means simplistic “telomere support” marketing is not an adequate safety assessment.

Older studies vs. modern products

Older epithalamin studies and animal studies often reported favorable tolerability, but those data do not define safety for synthetic epitalon sold online or compounded for modern clinical use^{[9 –16 ]}. Differences in product identity, salt form, purity, route, dose, sterility, and patient population matter.

Long-term safety data are insufficient. No large FDA-reviewed clinical program, pharmacokinetic package, reproductive safety package, carcinogenicity program, or postmarketing database was identified for epitalon^{[2 –7 ,17 –18 ]}.

Available through

Epitalon is not currently available through routine FDA-compliant prescription or compounding channels in the United States as of 2026-05-05^{[2 –7 ]}. It is not FDA-approved, is not on the 503A or 503B bulks lists, and awaits PCAC review scheduled for July 24, 2026^{[3 –4 ]}.

ProPeptideGuide does not link to or endorse grey-market vendors, research-chemical sellers, online peptide shops, imported epitalon products, or clinics advertising epitalon for anti-aging, telomere extension, sleep, longevity, or performance use.